HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
Autor: | Laura Sighinolfi, Guido Palamara, Massimo Di Pietro, Barbara Ensoli, Angela Arancio, Sonia Moretti, Mauro Magnani, Stefania Bellino, Fabrizio Ensoli, Vito S. Mercurio, Francesco Castelli, Leonardo Sernicola, Enrico Garaci, Maria Teresa Maggiorella, Andrea Gori, Giovanni Di Perri, Cecilia Sgadari, Massimo Galli, Vittorio Francavilla, Orietta Picconi, Anna Casabianca, Olimpia Longo, Chiara Orlandi, Aurelio Cafaro, Adriano Lazzarin, Antonella Tripiciano, Cristina Mussini, Maria Rosaria Pavone Cossut, Giovanni Paniccia, Gioacchino Angarano, Paolo Monini |
---|---|
Přispěvatelé: | Ensoli, F, Cafaro, A, Casabianca, A, Tripiciano, A, Bellino, S, Longo, O, Francavilla, V, Picconi, O, Sgadari, C, Moretti, S, Cossut, M, Arancio, A, Orlandi, C, Sernicola, L, Maggiorella, M, Paniccia, G, Mussini, C, Lazzarin, A, Sighinolfi, L, Palamara, G, Gori, A, Angarano, G, Di Pietro, M, Galli, M, Mercurio, V, Castelli, F, Di Perri, G, Monini, P, Magnani, M, Garaci, E, Ensoli, B |
Rok vydání: | 2015 |
Předmět: |
Male
HAART Antibodie HIV Antibodies CD38 Antibodies CD38+HLA-DR+/CD8+ T cells HIV-1 Neutralization Proviral DNA Tat protein Vaccine AIDS Vaccines Acquired Immunodeficiency Syndrome Adult Antibodies Neutralizing Antiretroviral Therapy Highly Active CD4 Lymphocyte Count Female Follow-Up Studies Humans Immunoglobulin G Immunoglobulin M Italy Leukocytes Middle Aged Treatment Outcome Young Adult tat Gene Products Human Immunodeficiency Virus Viral Load Virology Infectious Diseases Medicine + HLA-DR CD8 T cells Neutralizing biology Immunogenicity Vaccination CD38+HLA-DR+/CD8+ T cell Antibody tat Gene Products Viral load Human Immunodeficiency Virus Antiretroviral Therapy Viremia Immune system Highly Active business.industry Research medicine.disease Immunization Immunology biology.protein business |
Zdroj: | Retrovirology |
ISSN: | 1742-4690 |
Popis: | Background The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers. The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks. Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on 168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline, with plasma viremia |
Databáze: | OpenAIRE |
Externí odkaz: |